Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Cash from Financing Activities for 15 consecutive years, with $37.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 112.86% year-over-year to $37.3 million, compared with a TTM value of -$38.3 million through Dec 2025, up 92.13%, and an annual FY2025 reading of -$38.3 million, up 92.13% over the prior year.
  • Cash from Financing Activities was $37.3 million for Q4 2025 at Neurocrine Biosciences, down from $45.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $69.9 million in Q1 2024 and bottomed at -$293.0 million in Q2 2024.
  • Average Cash from Financing Activities over 4 years is -$34.2 million, with a median of $15.1 million recorded in 2021.
  • Peak annual rise in Cash from Financing Activities hit 752.44% in 2024, while the deepest fall reached 10203.45% in 2024.
  • Year by year, Cash from Financing Activities stood at $15.1 million in 2021, then surged by 134.44% to $35.4 million in 2023, then tumbled by 919.21% to -$290.0 million in 2024, then skyrocketed by 112.86% to $37.3 million in 2025.
  • Business Quant data shows Cash from Financing Activities for NBIX at $37.3 million in Q4 2025, $45.6 million in Q3 2025, and -$3.3 million in Q2 2025.